Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for treating non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have non-small cell lung cancer.
Checked against the public recordLast updated Jun 15, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Eastern Cooperative Oncology Group
- Interventions being studied
- Drug: carboplatin; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: paclitaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung carcinoma of any of the following subtypes: * Squamous cell * Adenocarcinoma * Large cell anaplastic * Bronchioalveolar * Non-small cell carcinoma not otherwise specified * No small cell anaplastic elements allowed * Must have: * Recurrent disease after prior radiotherapy or surgery OR * Stage IV disease with distant metastases OR * Stage IIIB disease presenting with pleural or pericardial effusion on CT or chest x-ray or pleural implants documented pathologically or on CT or chest x-ray * Bidimensionally measurable or evaluable disease * Brain metastases allowed provided clinically stable after treatment with surgery and/or radiotherapy PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 2 Life expectancy: * Not specified Hematopoietic: * Absolute neutrophil count at least 1,500/mm3 * Platelet count at least 100,000/mm3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 5 times upper limit of normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min Cardiovascular: * No uncontrolled high blood pressure, unstable angina, or congestive heart failure * No myocardial infarction within the past 6 months * No serious ventricular arrhythmias requiring medication Other: * Not pregnant or nursing * Fertile patients must use effective contraception * No other active malignancies requiring ongoing treatment * No uncontrolled serious active infections * No suspected hypersensitivity to agents that utilize Cremophor * No evidence of neuropathy grade 2 or greater by history or physical examination PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy for non-small cell lung cancer Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * No prior radiotherapy to only site of measurable or evaluable disease unless subsequent progression documented by physical exam, radiograph, or pathology * Recovered from prior radiotherapy * No concurrent radiotherapy except for whole brain radiation for developing brain metastases Surgery: * See Disease Characteristics
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Emory University Hospital - AtlantaAtlanta, Georgia
- Iowa Methodist Medical CenterDes Moines, Iowa
- Mercy Medical CenterDes Moines, Iowa
- Iowa Lutheran HospitalDes Moines, Iowa
- Alegent Health-Midlands Community HospitalPapillion, Nebraska
- CCOP - Northern New JerseyHackensack, New Jersey
- Cancer Institute of New JerseyNew Brunswick, New Jersey
- MBCCOP - University of New Mexico HSCAlbuquerque, New Mexico
- James P. Wilmot Cancer CenterRochester, New York
- CCOP - OklahomaTulsa, Oklahoma
- Milton S. Hershey Medical CenterHershey, Pennsylvania
- CCOP - Scott and White HospitalTemple, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 15, 2023. Always confirm current availability with the study team.